We know how many Nigerians have hypertension because a blood pressure cuff costs next to nothing and takes thirty seconds. We know the diabetes numbers because a glucose strip is cheap and the result is immediate. For cardiovascular disease beyond hypertension, for chronic lung disease, for chronic kidney disease — we have no such shortcut. The numbers we have are almost certainly wrong. And wrong in one direction only: too low.

That is not a small observation. It means the conditions most likely to go undetected are also the ones most likely to arrive late — already advanced, already compounding whatever else the patient is managing, and already far more expensive to treat.

The Measurement Problem

Low prevalence numbers for CVD, COPD, and CKD are cited as evidence that these conditions are less urgent than hypertension or diabetes. That reasoning is flawed. Low numbers, in contexts where diagnostic infrastructure barely exists, do not reflect low prevalence. They reflect low detection.

Nigeria has fewer than one functioning spirometer — the device required to definitively diagnose COPD — per tertiary hospital in most of the country. Kidney disease in its early stages produces no obvious symptoms, yet only 61.6% of people with kidney-related symptoms reach any healthcare facility at all. CVD research data is described in the scientific literature itself as “scanty.”

Cardiovascular Disease: Striking in the Productive Years

Forty percent of Nigerian adults live with hypertension, confirmed by the Federal Ministry of Health in March 2026. But hypertension is the gateway, not the destination. Stroke causes 47.2% of all CVD deaths. Heart failure accounts for a further 16.6%. A sixteen-year review of Lagos University Teaching Hospital found CVD-related deaths made up 30.4% of all hospital deaths — with a median patient age of 56.6. This is not a disease of the elderly. It strikes Nigerians in their most economically productive decade.

In-hospital mortality following acute coronary events stands at 8.1%, with one-year mortality at 13.3% — multiples of what is seen in better-resourced settings. Nigeria also carries the highest global burden of peripartum cardiomyopathy, a form of heart failure developing in women around the time of childbirth.

Chronic Lung Disease: The Invisible Epidemic

COPD is the third leading cause of death worldwide, affecting more than 400 million people globally. In Nigeria, prevalence sits at approximately 9% — a figure that, given the near-total absence of spirometry in public health facilities, is almost certainly an undercount.

Unlike high-income settings where tobacco dominates, chronic lung disease in Nigeria is driven heavily by environmental and occupational exposure: indoor air pollution, urban particulate matter, and high-dust or chemical work environments. The populations most affected are least likely to see a respiratory specialist. There is currently approximately one respiratory specialist for every 2.3 million Nigerians.

The result is a self-reinforcing cycle: no diagnostic equipment, so no diagnosis; no diagnosis, so no treatment; no treatment, so late-stage presentation and avoidable death.

Chronic Kidney Disease: When the Bill Arrives, It Is Unpayable

National CKD prevalence estimates range from 10% to nearly 20%. Patients in recent Nigerian cohorts are presenting in their third and fourth decades of life — dramatically younger than the profile seen in wealthy countries, where over half of CKD patients are aged 65 or above.

The treatment economics are devastating. A single haemodialysis session costs ₦30,000 to ₦50,000. End-stage patients require two to three sessions per week. Only 5% can sustain that cost beyond twelve weeks. National health insurance covers just six sessions per year for acute kidney injury — wholly inadequate for chronic disease.

80% of end-stage kidney disease patients die within weeks of diagnosis. Not from the disease. From the cost of treatment.

The Comorbidity Multiplier

These three conditions do not exist in isolation. They stack. A patient with uncontrolled hypertension is simultaneously accumulating cardiovascular risk, accelerating kidney decline, and — depending on environment and occupation — potentially developing respiratory disease as well. When comorbidities combine, they do not add linearly. They compound.

This compounding effect is one reason why conventional care — a visit, a prescription, a follow-up in six months — is structurally insufficient. There is also a more subtle dynamic conventional care almost entirely misses: the small signal. Patients experiencing early deterioration do not call a doctor for a slight shortness of breath, a week of unusual fatigue, or a modest but persistent weight gain. They live with it. They adapt. And in doing so, they allow a manageable drift to become an unmanageable crisis.

The Signals Are There

The reason these conditions progress undetected is not that the signals are absent. They are always there. A 2% weight gain over ten days. A change in sleep pattern. A small flare that does not feel urgent enough to call a doctor about. Individually, each means little. Tracked over time against a patient’s history, environment, and existing conditions, they begin to tell a story.

At Rikenda, our patients call us for those small things. Not because they are in crisis — because we have asked them to. And when they do, we do not reassure them and move on. We record it. We add it to their profile. We let the pattern build. And we act on what the pattern reveals, before the patient ever reaches the point where the cardiologist, the pulmonologist, or the nephrologist is their only remaining option.

The conditions that do not announce themselves require the most vigilant watching. That is not something a patient can do alone, or a doctor with a full waiting room can do in ten minutes. It is what a team is for.